Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Interest Expenses (2022 - 2025)

Historic Interest Expenses for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to $3.1 million.

  • Arcutis Biotherapeutics' Interest Expenses fell 5384.04% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year decrease of 5019.23%. This contributed to the annual value of $27.2 million for FY2024, which is 856.22% down from last year.
  • Arcutis Biotherapeutics' Interest Expenses amounted to $3.1 million in Q3 2025, which was down 5384.04% from $3.0 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Interest Expenses' 5-year high stood at $7.8 million during Q4 2023, with a 5-year trough of $1.8 million in Q1 2022.
  • Over the past 4 years, Arcutis Biotherapeutics' median Interest Expenses value was $6.7 million (recorded in 2024), while the average stood at $5.4 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first surged by 28313.38% in 2023, then tumbled by 6013.37% in 2025.
  • Over the past 4 years, Arcutis Biotherapeutics' Interest Expenses (Quarter) stood at $6.9 million in 2022, then grew by 12.25% to $7.8 million in 2023, then dropped by 28.48% to $5.6 million in 2024, then crashed by 44.68% to $3.1 million in 2025.
  • Its Interest Expenses was $3.1 million in Q3 2025, compared to $3.0 million in Q2 2025 and $3.0 million in Q1 2025.